MedTrace Logo

Monitoring and Early Response Evaluation Using HPV DNA - A Study on Patients With HPV-positive Throat Cancer (MER-HPV)

NCT05649865 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2023-06-08

No results posted yet for this study

Summary

The goal of this clinical trial is to determine the value of circulating tumour HPV DNA (human papilloma virus DNA found in the blood) at diagnosis, during treatment, and in the follow-up of patients diagnosed and treated for throat cancer caused by HPV.

The main question to answer is if the presence of HPV DNA in the blood one month after the treatment is useful in detecting remaining tumour or relapse within two years after treatment.

The participants will be asked to provide blood tests:

1. before treatment
2. weekly during the treatment
3. on all scheduled follow-up appointments
4. on all unplanned appointments where a relapse is suspected

Conditions

  • Oropharynx Squamous Cell Carcinoma

Interventions

DIAGNOSTIC_TEST

Blood sample

Blood samples for analysis of circulating tumour HPVDNA

Sponsors & Collaborators

  • Region Skane

    lead OTHER

Principal Investigators

  • Johanna Sjövall, MD,PhD · Dept. of clincial sciences, Lund University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-15
Primary Completion
2027-05-31
Completion
2028-05-31

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05649865 on ClinicalTrials.gov